

# Alvin W T Ng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9417990/publications.pdf>

Version: 2024-02-01

16  
papers

3,412  
citations

1040056

9  
h-index

996975

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

7527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of mutational signature software on correlated signatures. <i>Scientific Reports</i> , 2022, 12, 390.	3.3	6
2	Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas. <i>Communications Biology</i> , 2022, 5, 335.	4.4	8
3	Mutational processes in cancer preferentially affect binding of particular transcription factors. <i>Scientific Reports</i> , 2021, 11, 3339.	3.3	2
4	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. <i>Gastroenterology</i> , 2021, 161, 1705-1708.e2.	1.3	8
5	Alterations in the Ca <sup>2+</sup> toolkit in oesophageal adenocarcinoma. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, .	0.8	1
6	Characterization of colibactin-associated mutational signature in an Asian oral squamous cell carcinoma and in other mucosal tumor types. <i>Genome Research</i> , 2020, 30, 803-813.	5.5	32
7	The repertoire of mutational signatures in human cancer. <i>Nature</i> , 2020, 578, 94-101.	27.8	2,104
8	Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. <i>Genome Research</i> , 2019, 29, 521-531.	5.5	57
9	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OEO2 trial. <i>European Journal of Cancer</i> , 2019, 123, 48-57.	2.8	5
10	DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 43-43.	1.6	1
11	In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. <i>Genome Research</i> , 2018, 28, 654-665.	5.5	126
12	Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 22.	5.0	15
13	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 630-651.	9.4	48
14	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	272
15	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. <i>Genome Research</i> , 2017, 27, 1475-1486.	5.5	90
16	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135.	9.4	637